Trial Profile

A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary) ; Cannabidiol/tetrahydrocannabivarin-9 (Primary) ; Tetrahydrocannabivarin 9 (Primary)
Indications Dyslipidaemias; Type 2 diabetes mellitus
Focus Biomarker; Therapeutic Use
Sponsors GW Pharmaceuticals

29 Aug 2016 Results assessing effects of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters published in the Diabetes Care (2016).
05 May 2016 Results from this trial are expected in Q2/3 2016, according to a GW Pharmaceuticals media release.
28 Nov 2012 Primary endpoint 'HDL-cholesterol-level' has not been met based on information reported in a GW Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com